- Heavily pretreated patients with BRCA1/2-mutated ovarian cancer showed sensitivity for chemotherapy (CT), even in platinum-resistant setting.
- Primary platinum-free interval (PFI) >12 months, platinum-based CT (platinum-CT), and PARP inhibitors (PARPi) were associated with improved prognosis.
Why this matters
- Platinum resistance status based on
- 135 heavily pretreated patients with BRCA1/2+ ovarian cancer received CT.
- Patients were classified according to PFI after last platinum-CT (platinum-resistant,
- Median CT lines: 2.
- Funding: Vall d'Hebron Institute of Oncology.
- Median follow-up, 5.8 years.
- 6-year OS rate was similar between BRCA1 and BRCA2 mutation carriers (P=.98).
- Median time to progression (TTP) beyond second-line therapy was 10.2 (95% CI, 8.4-11.9) months in overall and 6.1 (95% CI, 4.5-7.7) months in platinum-resistant patients.
- Compared with non-platinum-CT (4.9 months), TTP significantly improved with platinum-CT+PARPi, platinum-CT, or PARPi (17.1, 12.6, 12.4 months, respectively; Pall<.001 in platinum-sensitive patients.>
- In platinum-resistant patients, TTP was not statistically different between treatments.
- Primary PFI >12 months (HR, 0.32; P=.01), platinum-CT (HR, 0.3; P<.001 and parpi p=".04)" were associated with improved outcomes.>
- Retrospective design.